

## **Contribution of biologically active products, Immuno-VIP and Immuno-CIP in the support and amelioration of psoriasis vulgaris symptoms**

Psoriasis has a major negative impact on the quality of patient's life.

This impact is often underestimated, having as an immediate effect their sub-optimal treatment. The negative impact is reflected on a wide array of parameters, as shown by a variety of studies: work/school activities, daily life, sexual activity, family relationships.

Psoriasis is statistically one of the three main pathologies (together with cardiac failure and high blood pressure) that influence the physical abilities of the affected individual and the second (beside depression) that influence the mental abilities of the affected individual.

Among skin pathology psoriasis occupies the first place in what concerns the deterioration of the quality of life (QoL) index, surpassing skin malignancies.

Psoriasis has, both physically and mentally, a debilitating influence on the daily life of affected individuals.

Up to date there is no curative treatment for psoriasis. The drugs used today produce suppression of the immune system, thus inducing remission of lesions or just reducing the clinical aspects to the threshold of supportability of the patient.

Psoriasis is a pathology with chronic evolution; once installed, the patients will have to deal with it for the rest of their life.

### **Contribution of biologically active products to support the amelioration of pediatric psoriasis symptoms**

The use of Immuno-VIP and Immuno-CIP is performed orally and topically,

In case of children that used Immuno-VIP and IMMUNO-CIP biological products it was noticed a potentiation of remission of their clinical pathology, in a relatively short time span. Skin and nail lesions and joint pain associated with psoriasis were diminished. The QoL of these patients improved and they reintegrated in their families and school communities. The use of Immuno-VIP and IMMUNO-CIP biological products supported patients effort to maintain disease control for up to 4 years.

For a permanent immunological support, a cure of 14 days, two times a year is recommended using oral administration of IMMUNO-VIP.

The use of the CIAP does not lead to anti-idiotypic reactions, neither anaphylactic reactions.



The use of biological products IMMUNO-VIP and IMMUNO-CIP for psoriasis vulgaris in children is based on the following particularities:

- Psoriasis is a whole body pathology;
- Psoriasis is a disease with immune system involvement in which the T lymphocyte participates with multiple immune functions;
- CIAP is applied orally and topically;
- CIAP may be applied for a long period, even after the improvement of the skin, nail or joint lesions;
- CIAP is based on a complex immune mechanism that support the process of recovery from ailments determined and maintained by a suppressed immune system.
- Should be used in combination with drugs as it does not interact with them, a potency of the drugs effect being observed.

IMMUNO-VIP biological products present the following advantages:

- ✓ Oral use;
- ✓ High molecular weight products that pass the mucosal epithelia in humans;
- ✓ Non-toxic to humans;
- ✓ well tolerated by the human organism;
- ✓ The use during a long period of time did not showed any risks.

***Warning! IMMUNO-VIP may not be used by individuals with egg allergy.***

### ***Selective references***

1. Ionel-Victor Pătrașcu, Liliana Viasu, Maria-Anca Petriu, Mircea Penescu, Carmen Balotescu-Chifiriuc, Maria Serdaru, Rareș- Ilieș Preutu, Sabina Petrică. Immunological active proteins I-spga. The specific reaction against Colistin resistance Klebsiella Pneumoniae strains. One Health International Journal, 2017; 3(2): 120-126. One Health New Medical Concept Association, Romania
2. Ionel Victor Pătrașcu, Constantin Chiurciu, Viorica Chirciu, Mariana Oporanu, Iuliana Mihai, Lucica Sima, Georgiana Radu, Georgiana Topilescu, Cristina Cășaru. Biological products PC2. Part 3. Active immunity via passive immunity. One Health International Journal, 2017; 3(2),116-119.
3. Pătrașcu I.V., Patent A00340/2017: compozitia si metoda de preparare a unui imunogen complex numit I-SPGA
4. Pătrașcu Ionel Victor, MVD, PhD. Active immunity by passive immunity. I-spga as a new Immunogen. A Modest Contribution to the Fight Against the Antimicrobial Resistance. SDG Lab, Davos, January 24, 2018; World Economic Forum Annual Meeting 23-26 January 2018, Davos-Klosters, Switzerland
5. Ionel Victor Pătrașcu, Liliana Viasu, Maria Serdaru, Ilies-Rares Preutu. Oral and Topical Treatment of Pediatric Psoriasis. 14th World Congress on Infection Prevention and Control (Theme: Novel Insights in Therapeutic Research on Infectious Diseases, Prevention and Control), December 6-7, 2018 Valencia, Spain

